Maropitant a neurokinin-1 (NK-1) receptor antagonist used as an antiemetic drug in dogs by blockade of substance P/NK-1 receptor binding in the vomiting center and chemoreceptor trigger zone in the central nervous sys...Maropitant a neurokinin-1 (NK-1) receptor antagonist used as an antiemetic drug in dogs by blockade of substance P/NK-1 receptor binding in the vomiting center and chemoreceptor trigger zone in the central nervous system. In addition,substance P and NK-1 receptors have been isolated in nociceptive pathways. Therefore,it is expected that maropitant provides analgesic effect and its sparing effect of minimum alveolar concentration (MAC) has been reported in dogs. The purpose of this study was to evaluate the sparing effect of an approved antiemetic dose of maropitant on the MAC for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs.Six adult healthy beagle dogs were anesthetized to determine the MAC-BAR of sevoflurane on 2-ocassions at least 1-week intervals. In each occasion,the dogs received a subcutaneous injection (SC) of saline (0. 1 ml/kg) or maropitant (1 mg/kg) before the MAC-BAR determination. MAC-BAR determination started at 60 min after the administration of saline or maropitant. MAC-BAR was determined in duplicate for each dog using electrical stimulus applied to the gingival (50 V,50 Hz,10 ms). During the MAC determination,all dogs were mechanically ventilated to maintain the endtidal CO2within 35 to 40 mmHg and kept warm to maintain esophageal temperature within 37. 5 to 38. 5 ℃. Data were compared between groups using a paired t-test. The level of significance was set at P < 0. 05.The baseline MAC-BAR for sevoflurane was 3. 44 ± 0. 53%. Subcutaneous maropitant significantly decreased the sevoflurane MAC-BAR by 17% (2. 88 ± 0. 74%,P = 0. 037).Maropitant decreased the sevoflurane MAC-BAR when administered at the approved antiemetic dose (1 mg/kg:SC) to dogs. It is expected that a preoperative administration of maropitant may produce anesthetic sparing effect in addition to antiemetic effect in dogs.展开更多
文摘Maropitant a neurokinin-1 (NK-1) receptor antagonist used as an antiemetic drug in dogs by blockade of substance P/NK-1 receptor binding in the vomiting center and chemoreceptor trigger zone in the central nervous system. In addition,substance P and NK-1 receptors have been isolated in nociceptive pathways. Therefore,it is expected that maropitant provides analgesic effect and its sparing effect of minimum alveolar concentration (MAC) has been reported in dogs. The purpose of this study was to evaluate the sparing effect of an approved antiemetic dose of maropitant on the MAC for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs.Six adult healthy beagle dogs were anesthetized to determine the MAC-BAR of sevoflurane on 2-ocassions at least 1-week intervals. In each occasion,the dogs received a subcutaneous injection (SC) of saline (0. 1 ml/kg) or maropitant (1 mg/kg) before the MAC-BAR determination. MAC-BAR determination started at 60 min after the administration of saline or maropitant. MAC-BAR was determined in duplicate for each dog using electrical stimulus applied to the gingival (50 V,50 Hz,10 ms). During the MAC determination,all dogs were mechanically ventilated to maintain the endtidal CO2within 35 to 40 mmHg and kept warm to maintain esophageal temperature within 37. 5 to 38. 5 ℃. Data were compared between groups using a paired t-test. The level of significance was set at P < 0. 05.The baseline MAC-BAR for sevoflurane was 3. 44 ± 0. 53%. Subcutaneous maropitant significantly decreased the sevoflurane MAC-BAR by 17% (2. 88 ± 0. 74%,P = 0. 037).Maropitant decreased the sevoflurane MAC-BAR when administered at the approved antiemetic dose (1 mg/kg:SC) to dogs. It is expected that a preoperative administration of maropitant may produce anesthetic sparing effect in addition to antiemetic effect in dogs.
